Celgene Will Discontinue Phase III MAINSAIL® Trial in Castrate-Resistant Prostate Cancer

by Benzinga Staff
November 22, 2011 4:46 PM | 16 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) announced that based on the recommendation from the Data MonitoringCommittee it will discontinue its pivotal double-blinded Phase IIIMAINSAIL trial that was designed to evaluate the efficacy and safety ofdocetaxel and prednisone with or without lenalidomide in patients withcastrate-resistant prostate cancer.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.